NEW YORK – Spanish cancer IVD developing Universal Diagnostics has shifted it commercial strategy from using mass spectrometry for early cancer detection to a liquid biopsy approach that identifies DNA methylation biomarkers to detect precancerous cells in patient blood samples that may indicate early-stage colorectal cancer (CRC) or other tumors.
Spain's Universal Diagnostics Bets on Cell-Free DNA Methylation for Early-Stage Cancer Detection
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.